PL358253A1 - Sposób wytwarzania krystalicznej formy I kabergoliny - Google Patents

Sposób wytwarzania krystalicznej formy I kabergoliny

Info

Publication number: PL358253A1
Authority: PL; Poland
Prior art keywords: cabergoline; crystalline form; preparing crystalline; preparing; crystalline
Prior art date: 2000-03-24

Application number

PL01358253A

Other languages

English (en)

Inventor

Attilio Tomasi

Stefania Magenes

Mario Ungari

Giuliano Ramella

Gianfranco Pallanza

Original Assignee

Pharmacia Italia S.P.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-24

Filing date

2001-03-19

Publication date

2004-08-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL358253(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-19 Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.

2004-08-09 Publication of PL358253A1 publication Critical patent/PL358253A1/pl

Links

KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 title 1
229960004596 cabergoline Drugs 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PL01358253A 2000-03-24 2001-03-19 Sposób wytwarzania krystalicznej formy I kabergoliny PL358253A1 (pl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0007308.0A GB0007308D0 (en)	2000-03-24	2000-03-24	Process for preparing crystalline form \| of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en)	2000-03-24	2001-03-19	Process for preparing crystalline form i of cabergoline

Publications (1)

Publication Number	Publication Date
PL358253A1 true PL358253A1 (pl)	2004-08-09

Family

ID=9888433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL01358253A PL358253A1 (pl)	2000-03-24	2001-03-19	Sposób wytwarzania krystalicznej formy I kabergoliny

Country Status (31)

Country	Link
US (2)	US6727363B2 (pl)
EP (1)	EP1272489B1 (pl)
JP (1)	JP4184666B2 (pl)
KR (1)	KR100827558B1 (pl)
CN (1)	CN1188412C (pl)
AR (1)	AR032449A1 (pl)
AT (1)	ATE250601T1 (pl)
AU (2)	AU780747B2 (pl)
BR (1)	BR0109507A (pl)
CA (1)	CA2402836A1 (pl)
CZ (1)	CZ20023176A3 (pl)
DE (1)	DE60100858T2 (pl)
DK (1)	DK1272489T3 (pl)
EA (1)	EA005928B1 (pl)
EE (1)	EE05088B1 (pl)
ES (1)	ES2208602T3 (pl)
GB (1)	GB0007308D0 (pl)
HK (1)	HK1052348B (pl)
HU (1)	HUP0300591A3 (pl)
IL (2)	IL150985A0 (pl)
MX (1)	MXPA02009283A (pl)
MY (1)	MY134189A (pl)
NO (1)	NO20024321L (pl)
NZ (1)	NZ521316A (pl)
PE (1)	PE20011140A1 (pl)
PL (1)	PL358253A1 (pl)
PT (1)	PT1272489E (pl)
SI (1)	SI1272489T1 (pl)
SK (1)	SK13582002A3 (pl)
WO (1)	WO2001070740A1 (pl)
ZA (1)	ZA200206045B (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007307D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
MXPA04008915A (es) *	2002-03-15	2005-06-20	Pharmacia Corp	Proceso para la preparacion de la forma cristalina 1 de la cabergolina.
KR100605794B1 (ko) *	2002-03-15	2006-08-01	파마시아 코포레이션	카베르골린의 제1형 결정을 제조하는 방법
IL155545A (en)	2003-04-21	2009-12-24	Finetech Pharmaceutical Ltd	Solvate form of cabergoline
EP1620101A4 (en) *	2003-05-08	2008-07-09	Ivax Pharmaceuticals Sro	POLYMORPHS OF CABERGOLIN
GB0409785D0 (en) *	2004-04-30	2004-06-09	Resolution Chemicals Ltd	Preparation of cabergoline
US7339060B2 (en)	2005-03-23	2008-03-04	Resolution Chemicals, Ltd.	Preparation of cabergoline
GB0515430D0 (en) *	2005-07-27	2005-08-31	Resolution Chemicals Ltd	Preparation of cabergoline
GB0505965D0 (en)	2005-03-23	2005-04-27	Resolution Chemicals Ltd	Preparation of cabergoline
EP1925616A1 (en) *	2006-10-26	2008-05-28	LEK Pharmaceuticals D.D.	Process for the preparation of crystal forms of cabergoline via stable solvates of cabergoline
EP1953157A1 (en)	2007-01-31	2008-08-06	LEK Pharmaceuticals D.D.	New crystal form of cabergoline
EP2185169A2 (en) *	2007-08-29	2010-05-19	Max Zeller Söhne AG	Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (en) *	2021-04-16	2024-04-03	Thermo King LLC	Electrical connection unit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3019322A1 (de)	1980-05-21	1981-12-03	Merck Patent Gmbh, 6100 Darmstadt	Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en)	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) *	1981-08-11	1985-04-11	Erba Farmitalia	Ergoline derivatives
GB9205439D0 (en) *	1992-03-12	1992-04-22	Erba Carlo Spa	Process for the synthesis of ergoline derivatives
WO1995005176A1 (en)	1993-08-18	1995-02-23	Alcon Laboratories, Inc.	Use of ergoline derivatives for the treatment of glaucoma
EP1075278A1 (en)	1998-01-13	2001-02-14	AstraZeneca UK Limited	PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D 2?) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING $g(b) 2?-ADRENORECEPTOR AGONIST ACTIVITY
SK13312000A3 (sk)	1998-03-27	2001-05-10	Pharmacia And Upjohn Company	Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007307D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline
GB0007309D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline

2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en not_active Ceased
- 2001-03-19 EP EP01936098A patent/EP1272489B1/en not_active Expired - Lifetime
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 PL PL01358253A patent/PL358253A1/pl not_active Application Discontinuation
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active Expired - Fee Related
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321L/no not_active Application Discontinuation
2003
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased

Also Published As

Publication number	Publication date
SK13582002A3 (sk)	2003-04-01
US6953854B2 (en)	2005-10-11
AU2005203071B2 (en)	2007-10-18
KR20020081587A (ko)	2002-10-28
MY134189A (en)	2007-11-30
EE200200545A (et)	2004-04-15
ATE250601T1 (de)	2003-10-15
PT1272489E (pt)	2004-02-27
DK1272489T3 (da)	2003-12-15
US6727363B2 (en)	2004-04-27
EA005928B1 (ru)	2005-08-25
NZ521316A (en)	2004-05-28
US20030149067A1 (en)	2003-08-07
SI1272489T1 (en)	2004-02-29
MXPA02009283A (es)	2003-03-12
PE20011140A1 (es)	2001-11-01
NO20024321D0 (no)	2002-09-10
EE05088B1 (et)	2008-10-15
ZA200206045B (en)	2003-07-29
CN1419554A (zh)	2003-05-21
IL150985A0 (en)	2003-02-12
GB0007308D0 (en)	2000-05-17
HK1052348B (zh)	2005-09-16
DE60100858T2 (de)	2004-07-29
CN1188412C (zh)	2005-02-09
AU780747B2 (en)	2005-04-14
AR032449A1 (es)	2003-11-12
IL150985A (en)	2007-03-08
JP4184666B2 (ja)	2008-11-19
JP2003528100A (ja)	2003-09-24
AU2005203071A1 (en)	2005-08-11
EP1272489A1 (en)	2003-01-08
CZ20023176A3 (cs)	2003-02-12
WO2001070740A1 (en)	2001-09-27
EP1272489B1 (en)	2003-09-24
KR100827558B1 (ko)	2008-05-07
HK1052348A1 (en)	2003-09-11
DE60100858D1 (de)	2003-10-30
US20040092744A1 (en)	2004-05-13
NO20024321L (no)	2002-09-10
HUP0300591A3 (en)	2009-01-28
HUP0300591A2 (hu)	2003-07-28
EA200201016A1 (ru)	2003-02-27
AU6211001A (en)	2001-10-03
ES2208602T3 (es)	2004-06-16
BR0109507A (pt)	2002-12-10
CA2402836A1 (en)	2001-09-27

Legal Events

Date	Code	Title	Description
2010-04-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
IL150985A0 (en)	2003-02-12	Process for preparing crystalline form i of cabergoline
EP1425279A4 (en)	2005-10-26	PROCESS FOR THE PREPARATION OF CRYSTALLINE TETRAHYDROBENZOTHIEPINES
EG23819A (en)	2007-09-19	Method for preparing of l-phenylephrine-hydrochloride
IL147244A0 (en)	2002-08-14	Process for preparing substituted cyclopentane derivatives and novel crystalline structures thereof
GB0016002D0 (en)	2000-08-23	Novel process for preparing crystalline particles
GB0007307D0 (en)	2000-05-17	Crystalline form \|\| of cabergoline
SG99351A1 (en)	2003-10-27	Process for the manufacture of a crystalline solid
HUP0300160A3 (en)	2005-07-28	Process for preparing (+)-cis-sertraline
GB0007309D0 (en)	2000-05-17	Crystalline form V\|\| of cabergoline
HUP0104405A3 (en)	2004-01-28	Process for preparing imidachlopid
HUP0300114A3 (en)	2005-11-28	Process for preparing flavonoid-derivatives
IL163520A0 (en)	2005-12-18	Process for preparing crystalline form i of cabergoline
HUP0303907A3 (en)	2012-09-28	Improved process for preparation of steroids
IL163779A0 (en)	2005-12-18	Process for preparing crystalline form i of cabergoline
HUP0101875A3 (en)	2002-11-28	Process for the preparation of piperidine derivatives
AU2001289303A1 (en)	2002-02-18	Process for producing crystalline tagatose
HUP0303832A3 (en)	2005-02-28	Process for preparation of baccatin iii derivatives
HU0101722D0 (en)	2001-07-30	Process for producing of chocolate
HU0103554D0 (en)	2002-01-28	Method for production of methylene-karbamide polimers
IL151632A0 (en)	2003-04-10	Process for preparing pure crystalline lorazepam
HU0104563D0 (en)	2002-01-28	Process for producing of food-enzymes
HUP0000366A3 (en)	2001-12-28	Process for producing heterocyclic compounds
HUP0004469A3 (en)	2002-08-28	Process for producing trifluormethyl-aniline derivatives
HUP0000208A3 (en)	2002-02-28	Process for producing secondary-alkoxy-1-alkene derivatives
HU9904575D0 (en)	2000-02-28	Process for preparation of n-alkoxy-methyl-acidamides